肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

什么是节拍化疗？节拍化疗在乳腺癌和肺癌中的研究汇总

2020-07-29 MedSci原创 MedSci原创

乳腺癌节拍化疗
关注

1971年美国哈佛医学院Folkman教授首次大胆地提出抑制肿瘤血管新生可以抑制肿瘤组织持续生长转移的假说，随着研究的深入，发现如果能够连续性给予低剂量的化疗药物，可能通过有效抑制肿瘤血管生长而控制肿

1971年美国哈佛医学院Folkman教授首次大胆地提出抑制肿瘤血管新生可以抑制肿瘤组织持续生长转移的假说，随着研究的深入，发现如果能够连续性给予低剂量的化疗药物，可能通过有效抑制肿瘤血管生长而控制肿瘤。加拿大多伦多大学学者Kerbel提出了节拍化疗（metronomic chemotherapy）的概念，指采用低剂量化疗药物，即相当于常规剂量的1/10～1/3，不间断、持续性或高频率（每周1～3次）给药，以肿瘤内活化内皮细胞为治疗靶点的化疗模式。由于节拍化疗给药频繁，靶标主要是肿瘤内活化的血管内皮细胞，而不再是肿瘤细胞。 由于给药剂量降低，节拍化疗具有低化疗毒副作用、低耐药性、方便长期给药、低治疗费用等优点。口服化疗药物由于其方便服用，更适合作节拍化疗。其中，代表性的药物有长春瑞滨、甲氨蝶呤、环磷酰胺、S-1、卡培他滨。 一. 节拍化疗的作用机制 相比于传统化疗，节拍化疗为多靶点疗法，其对肿瘤细胞及其微环境发挥着直接和间接作用，这些部分之间复杂的相互作用可能提高抗肿瘤作用，并潜在诱导肿瘤休眠。节拍化疗的抗肿瘤作用机制主要体现在以下三个方面： 第一，对肿瘤的直接作用：体外模型

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=806153, encodeId=70ee806153a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Aug 04 17:04:05 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805992, encodeId=ecef8059926c, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/c6630f4b5aef4b08b01fcfeb85397f71/d0947322e7fe488f91307f14dc5ffc93.jpg, createdBy=1db72531364, createdName=12501267m20暂无昵称, createdTime=Mon Aug 03 23:41:13 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805211, encodeId=fbdd805211c5, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1415403073, createdName=ms8000002066695668, createdTime=Thu Jul 30 16:25:53 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805171, encodeId=7ecb8051e1fe, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200730/0796f7e875f34e9fa3ee1d7b9da19c2b/711d476a19144354a05a422d24d495ec.jpg, createdBy=2d425268433, createdName=新斯的明, createdTime=Thu Jul 30 11:07:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805131, encodeId=1f1a80513126, content=<a href='/topic/show?id=5fe1103e7293' target=_blank style='color:#2F92EE;'>#节拍化疗#</a>总结全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103772, encryptionId=5fe1103e7293, topicName=节拍化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:43:02 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-08-04 phoebeyan520

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=806153, encodeId=70ee806153a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Aug 04 17:04:05 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805992, encodeId=ecef8059926c, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/c6630f4b5aef4b08b01fcfeb85397f71/d0947322e7fe488f91307f14dc5ffc93.jpg, createdBy=1db72531364, createdName=12501267m20暂无昵称, createdTime=Mon Aug 03 23:41:13 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805211, encodeId=fbdd805211c5, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1415403073, createdName=ms8000002066695668, createdTime=Thu Jul 30 16:25:53 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805171, encodeId=7ecb8051e1fe, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200730/0796f7e875f34e9fa3ee1d7b9da19c2b/711d476a19144354a05a422d24d495ec.jpg, createdBy=2d425268433, createdName=新斯的明, createdTime=Thu Jul 30 11:07:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805131, encodeId=1f1a80513126, content=<a href='/topic/show?id=5fe1103e7293' target=_blank style='color:#2F92EE;'>#节拍化疗#</a>总结全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103772, encryptionId=5fe1103e7293, topicName=节拍化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:43:02 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-08-03 12501267m20暂无昵称

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=806153, encodeId=70ee806153a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Aug 04 17:04:05 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805992, encodeId=ecef8059926c, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/c6630f4b5aef4b08b01fcfeb85397f71/d0947322e7fe488f91307f14dc5ffc93.jpg, createdBy=1db72531364, createdName=12501267m20暂无昵称, createdTime=Mon Aug 03 23:41:13 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805211, encodeId=fbdd805211c5, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1415403073, createdName=ms8000002066695668, createdTime=Thu Jul 30 16:25:53 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805171, encodeId=7ecb8051e1fe, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200730/0796f7e875f34e9fa3ee1d7b9da19c2b/711d476a19144354a05a422d24d495ec.jpg, createdBy=2d425268433, createdName=新斯的明, createdTime=Thu Jul 30 11:07:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805131, encodeId=1f1a80513126, content=<a href='/topic/show?id=5fe1103e7293' target=_blank style='color:#2F92EE;'>#节拍化疗#</a>总结全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103772, encryptionId=5fe1103e7293, topicName=节拍化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:43:02 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-07-30 ms8000002066695668

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=806153, encodeId=70ee806153a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Aug 04 17:04:05 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805992, encodeId=ecef8059926c, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/c6630f4b5aef4b08b01fcfeb85397f71/d0947322e7fe488f91307f14dc5ffc93.jpg, createdBy=1db72531364, createdName=12501267m20暂无昵称, createdTime=Mon Aug 03 23:41:13 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805211, encodeId=fbdd805211c5, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1415403073, createdName=ms8000002066695668, createdTime=Thu Jul 30 16:25:53 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805171, encodeId=7ecb8051e1fe, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200730/0796f7e875f34e9fa3ee1d7b9da19c2b/711d476a19144354a05a422d24d495ec.jpg, createdBy=2d425268433, createdName=新斯的明, createdTime=Thu Jul 30 11:07:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805131, encodeId=1f1a80513126, content=<a href='/topic/show?id=5fe1103e7293' target=_blank style='color:#2F92EE;'>#节拍化疗#</a>总结全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103772, encryptionId=5fe1103e7293, topicName=节拍化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:43:02 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-07-30 新斯的明

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=806153, encodeId=70ee806153a3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Aug 04 17:04:05 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805992, encodeId=ecef8059926c, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/c6630f4b5aef4b08b01fcfeb85397f71/d0947322e7fe488f91307f14dc5ffc93.jpg, createdBy=1db72531364, createdName=12501267m20暂无昵称, createdTime=Mon Aug 03 23:41:13 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805211, encodeId=fbdd805211c5, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1415403073, createdName=ms8000002066695668, createdTime=Thu Jul 30 16:25:53 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805171, encodeId=7ecb8051e1fe, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200730/0796f7e875f34e9fa3ee1d7b9da19c2b/711d476a19144354a05a422d24d495ec.jpg, createdBy=2d425268433, createdName=新斯的明, createdTime=Thu Jul 30 11:07:25 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805131, encodeId=1f1a80513126, content=<a href='/topic/show?id=5fe1103e7293' target=_blank style='color:#2F92EE;'>#节拍化疗#</a>总结全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103772, encryptionId=5fe1103e7293, topicName=节拍化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:43:02 CST 2020, time=2020-07-30, status=1, ipAttribution=)]
    2020-07-30 lovetcm

    #节拍化疗#总结全面

    0

相关资讯

中国专家为晚期难治性“最毒”乳腺癌患者燃起“生命之光”

三阴性乳腺癌被称为“最毒、最凶险”的乳腺癌，有不少患者经过多轮治疗、仍发生进展，面对“无药可救”的绝境。

谈乳腺癌治疗相关的“骨安全”管理

中国乳腺癌诊疗成绩斐然，5年生存率83.20%居十八大癌症首位，部分城市地区5年生存率甚至超过欧美国家的平均水平。与此同时，乳腺癌因非癌症原因影响生存。

JAMA：药物预防乳腺癌，哪些因素要权衡，四款药物怎么选？

乳腺癌是女性中的常见高发癌种，也是女性恶性肿瘤死亡的主要原因之一。乳腺癌筛查是疾病早期发现的重要手段，但并不能延缓疾病进展，而已有数款药物可以有效降低乳腺癌的发病风险。

Nat Commun ：全麻药在动物模型上通过IL-6通路影响乳腺癌转移

对恶性程度高的肿瘤如三阴性乳腺癌而言，即使完全切除了肿瘤及其累及的局部区域，癌症依然会复发或转移，成为导致病人死亡的主要原因。越多的研究表明手术围术期的用药和治疗会导致血液循环中的肿瘤细胞增多增强。

Dev Cell ：利用谱系示踪技术无缝隙捕捉体内肿瘤转移中的EMT过程

由于乳腺癌细胞丧失了正常的细胞特性，细胞之间的连接变得松散，容易脱落，进入血液系统或者淋巴系统进行转移，在远端器官，如肺，骨，肝等器官处形成转移灶，威胁患者生命。对乳腺癌转移方式及其机理的研究意义重大

JAMA：绝经后激素干预对女性乳腺癌发病率及死亡率的影响

长期随访发现，对于子宫切除的绝经后女性，接受结合雌激素可降低乳腺癌发病率和死亡率，但对于保留子宫的参与者，激素干预会增加乳腺癌发病率